Dulaglutide vs NAD+
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →NAD+
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. NAD+ levels naturally decline with age, and restoring them has become a major focus of longevity research. Injectable NAD+ bypasses the GI tract for higher bioavailability compared to oral precursors like NMN or NR.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | NAD+ |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | NAD+ is a critical substrate for sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, inflammation regulation, and mitochondrial function. It also serves as a coenzyme for PARP enzymes (involved in DNA damage repair) and CD38 (involved in immune cell signaling). By directly replenishing cellular NAD+ pools, injectable NAD+ supports mitochondrial electron transport chain function, enhances ATP production, and activates longevity-associated pathways. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Subcutaneous injection, typically 2–3 times per week. Start low and escalate: Twice per week protocol: Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 120 mg maintenance (0.6 ml). Three times per week protocol (e.g. Mon/Wed/Fri): Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 80 mg maintenance (0.4 ml). Volumes above assume 200 mg/ml concentration (100 mg vial reconstituted with 0.5 ml BAC water). Inject slowly — rapid administration increases flushing and nausea. Avoid back-to-back injection days. IV infusion (clinical setting): 250–750 mg per session over 2–4 hours. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Subcutaneous injection is the most practical route for self-administration. Inject slowly — rapid administration increases side effects (flushing, chest tightness, nausea). Some users split larger doses across multiple daily injections to improve tolerance. IV infusions provide the highest bioavailability but require a clinical setting. Store reconstituted NAD+ refrigerated and protect from light. NAD+ solutions are pH-sensitive; use bacteriostatic water for reconstitution. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Flushing and warmth (very common, especially at higher doses or fast injection rates). Nausea and mild GI discomfort. Chest tightness or pressure during injection (usually transient). Injection site pain or redness. Headache. These side effects are typically dose-dependent and diminish with slower administration and repeated use. |
| Best For |
Key Differences
Unique to Dulaglutide:
Ready to Learn More?
Looking for trusted sources?